Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.
about
Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.Recommended reading in population pharmacokinetic pharmacodynamicsApplication of population pharmacokinetics to cladribine.Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisApplication of NONMEM to routine bioavailability data.Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataPopulation pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1Pharmacokinetics of clindamycin in pregnant women in the peripartum period.The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humansPharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf.Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaInterpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Population pharmacokinetics of amikacin in critically ill patients.Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trialRelationships among liver and kidney volumes, lean body mass and drug clearance.Population pharmacokinetics I: background, concepts, and models.Population pharmacokinetics II: estimation methods.Invasiveness of pharmacokinetic studies in children: a systematic reviewShrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impactPopulation pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patientsAnalysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.Population pharmacokinetic analysis of carboxyhaemoglobin concentrations in adult cigarette smokersEvaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods.Population pharmacokinetic data and parameter estimation based on their first two statistical moments.Estimation of population pharmacokinetic parameters using destructively obtained experimental data: a simulation study of the one-compartment open model.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?A nonparametric subject-specific population method for deconvolution: I. Description, internal validation, and real data examples.A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.Pharmacokinetics of amoxicillin in maternal, umbilical cord, and neonatal sera.The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women.Cyclosporine-inhibitable blood-brain barrier drug transport influences clinical morphine pharmacodynamics.Development of a population pharmacokinetic model of prucalopride in children with functional constipation.Quantitative Assessment of Population Variability in Hepatic Drug Metabolism Using a Perfused Three-Dimensional Human Liver Microphysiological System.
P2860
Q24538612-B8606913-940F-4FDC-9577-751040FA0259Q24647906-2838483D-E171-435E-AE6D-CD699D99B21CQ24794793-AAFA42F8-91A6-4019-9F00-618773A7A850Q30489162-034BE0F1-A9B2-4BF5-9885-8BFBB7CC260FQ30597644-233BE1D5-88F0-4F5E-B3BD-C3F9C8069F76Q30666721-0258945C-B55A-4C4F-8954-B36191561BD6Q33392206-8919195A-535E-4AF1-91C3-3A7B8EEC631AQ33571417-E2C8F23C-4192-4B73-AC5C-DEBA122FD47AQ33693467-BBD0CA37-D517-4602-BEE3-9561C3FDE11BQ33802477-B7EA8297-1347-4046-8354-64D2E0E71B5BQ33826411-C262E9D1-FE00-44CF-AE64-BB525E7EC97EQ34347554-AADFC1A2-D9EE-4A74-9597-2B3563AE06D1Q34554442-EB0AC536-DCC0-4C52-8C38-E860CF89C390Q34609009-2E9C057A-5F7A-49DF-BE43-C023EDC494C4Q34644820-FE0C4B85-CB95-4F57-8E4D-0804834F269FQ34996894-A6171108-2D08-4D6C-954B-0FC2B1801C8EQ35125654-1D7BC8AE-7565-40D3-96DF-AF3F08915FF2Q35135977-5F643672-8F0C-4C6B-9F80-5B56E496F31CQ35154416-3FB01C87-4D0A-4E67-8244-C22A3F717520Q35802646-C4578CC0-22D4-4011-BF26-DCF09DDADCEBQ35870696-D8635204-AD66-4A7D-9060-EDC5959B8C3FQ35887615-37C9697D-8B9C-4903-9D57-4509DDE9155AQ36081153-7AD83CC7-D2CA-40A5-AC0C-5096E8270706Q36331482-6F068EFB-8A47-4369-B5ED-81F801FDED1AQ36390282-D623202E-0076-443B-9F05-8C6C387037B6Q36468048-25ADF778-4B8F-440A-8BB3-92DC9F9EF8A6Q36484805-2260CF76-E712-4D60-8378-DFD4A59CA3A6Q36536057-C0ADA141-C0FA-4275-BBB3-7D6B71DF3315Q36619254-BABB9B67-9216-4A18-81F2-CABF94537E24Q36627163-9E7AC8F4-BEC8-4107-8DAC-3EFD9996962DQ36627168-A75AC0A1-80D7-4C21-AC66-ED22F2EFEF45Q36627173-0E308A37-C63F-4896-AA67-2CF0DCE94FC4Q36628026-E33EBCB2-1406-44E0-9E80-6D3B62EB1527Q36810548-F42550DF-31D9-47A9-B6CB-FA9806B0F2A5Q36825493-AB29F78F-96E2-43FD-A606-F4812D1D6723Q37144784-C61B7603-39DC-4231-B2A3-E9C19C42EB8CQ37175822-4EFE25B9-E312-4E35-B7A9-DB42770F61C0Q37297410-B6012EAC-74C6-403F-BD22-3AFF3FB6E841Q37421978-0DE48EF8-0194-4461-B8EE-BC53B2257903Q37540180-8F96D184-AE95-4B36-9D8D-C9072BE26018
P2860
Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.
description
1981 nî lūn-bûn
@nan
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
1981年论文
@zh
1981年论文
@zh-cn
name
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@ast
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@en
type
label
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@ast
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@en
prefLabel
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@ast
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@en
P356
P1476
Evaluation of methods for esti ...... rimental pharmacokinetic data.
@en
P2093
P2888
P304
P356
10.1007/BF01061030
P577
1981-10-01T00:00:00Z